20
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Green Renal Replacement Therapy: Caring for the Environment

      Submit here before July 31, 2024

      About Blood Purification: 3.0 Impact Factor I 5.6 CiteScore I 0.83 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Utility of Cardiac Biomarkers in the Setting of Kidney Disease

      review-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Cardiovascular disease is prevalent in patients with chronic kidney disease (CKD) and responsible for approximately half of all CKD-related deaths. Unfortunately, the presence of CKD can lead to a challenging interpretation of cardiac biomarkers essential in accurate diagnosis and prompt management of heart failure and acute coronary syndrome. There is growing interest in novel cardiac biomarkers that may improve diagnostic accuracy reflecting myocardial injury, inflammation, and remodeling. Interpretation of these biomarkers in CKD can be complicated, since elevated levels may not reflect myocardial injury or wall tension but rather decreased urinary clearance with retention of solutes and/or overall CKD-associated chronic inflammation. In this review, we discuss the latest data on major and emerging cardiac biomarkers including B-type natriuretic peptide, troponin, suppression of tumorigenicity 2, growth and differentiation factor-15, galectin-3, and matrix gla protein, and their diagnostic and prognostic utility in the CKD population.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          2019
          April 2019
          06 February 2019
          : 141
          : 4
          : 227-235
          Affiliations
          [_a] aDepartment of Internal Medicine, Riverside Community Hospital, University of California, Riverside School of Medicine, Riverside, California, USA
          [_b] bDivision of Cardiology, University of California, Irvine School of Medicine, Irvine, California, USA
          [_c] cNational Research Council (CNR), Institute of Clinical Physiology (IFC), Pisa, Italy
          [_d] dDepartment of Medicine, University of Padova, Padova, Italy
          [_e] eNephrology and Dialysis Unit, Department of Clinical and Biomedical Sciences “Luigi Sacco”, University of Milan, Milan, Italy
          [_f] fDivision of Nephrology, University of California, Irvine School of Medicine, Irvine, California, USA
          Author notes
          *Wei Ling Lau, Division of Nephrology, University of California, 333 City Blvd. West, Suite 400, Irvine, CA 92868 (USA), E-Mail wllau@uci.edu
          Article
          495946 Nephron 2019;141:227–235
          10.1159/000495946
          30726855
          ed1fc204-094f-434b-b933-31b862eeb150
          © 2019 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 20 July 2018
          : 03 December 2018
          Page count
          Tables: 1, Pages: 9
          Categories
          Clinical Practice: Review

          Cardiovascular Medicine,Nephrology
          Biomarkers,Heart failure,Myocardial ischemia,Mortality,Chronic kidney disease

          Comments

          Comment on this article